Marker Therapeutics(DE:GX1)
€0.81+0.01 (+0.63%)
DE:GX1
Marker Therapeutics financials statements
€0.81
At close:+0.01 (+0.63%)
Marker Therapeutics (GX1) Income Statement
1 Followers
Marker Therapeutics Income Statement
Last quarter (Q2 2026), Marker Therapeutics's total revenue was $0.00, a decrease of 100.00% from the same quarter last year. In Q2, Marker Therapeutics's net income was $-1.83M. See Marker Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 6.59M | $ 3.31M | $ 3.51M | $ 1.24M | |
| $ 0.00 | $ -6.88M | $ -7.11M | $ -8.45M | $ -1.92M | |
| $ 12.89M | $ 4.24M | $ 7.48M | $ 11.34M | $ 37.56M | |
| Depreciation and Amortization | $ 0.00 | $ 2.00 | $ 2.79M | $ 3.68M | $ 3.16M |
| $ -12.44M | $ -10.68M | $ -11.25M | $ -16.10M | $ -38.72M | |
| $ -12.89M | $ -11.12M | $ -14.58M | $ -19.79M | $ -39.48M | |
| $ 711.65K | $ 437.01K | $ 539.16K | $ 15.09K | $ -2.40M | |
| $ -12.18M | $ -10.68M | $ -14.04M | $ -19.78M | $ -41.88M | |
| $ -12.16M | $ -10.73M | $ -8.24M | $ -29.93M | $ -41.88M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.79 | $ -1.19 | $ -1.93 | $ -3.58 | $ -5.47 |
| Diluted EPS | $ -0.79 | $ -1.19 | $ -1.93 | $ -3.58 | $ -5.47 |
| Weighted Average Shares Outstanding | 15.31M | 8.98M | 8.81M | 8.35M | 7.65M |
| Weighted Average Shares Outstanding (Diluted) | 15.31M | 8.98M | 8.81M | 8.35M | 7.65M |
Currency in USD
